HK2 and hepatocellular carcinoma: GalNac acts as a satisfactory siRNA delivery vehicle, and GalNac‐conjugated siRNAs against hepatocyte‐deregulated genes have been approved by the FDA for the treatment of various liver‐related diseases[21] or have entered phase III clinical trials.[22] HK2 is underexpressed in adult hepatocytes but is highly expressed in HCC.